How to buy Ardelyx stock | 5.83

Ardelyx, Inc is a biotechnology business based in the US. Ardelyx shares (ARDX) are listed on the NASDAQ and all prices are listed in US Dollars. Ardelyx employs 88 staff and has a trailing 12-month revenue of around USD$8.3 million.

How to buy shares in Ardelyx

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Ardelyx. Find the stock by name or ticker symbol: ARDX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ardelyx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$5.83, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ardelyx, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Ardelyx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Ardelyx's share price?

Since the stock market crash in March caused by coronavirus, Ardelyx's share price has had significant negative movement.

Its last market close was USD$5.83, which is 27.31% down on its pre-crash value of USD$8.02 and 38.15% up on the lowest point reached during the March crash when the shares fell as low as USD$4.22.

If you had bought USD$1,000 worth of Ardelyx shares at the start of February 2020, those shares would have been worth USD$794.48 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$804.13.

Ardelyx share price

Use our graph to track the performance of ARDX stocks over time.

Ardelyx shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$5.83
52-week range	USD$4.22 - USD$8.815
50-day moving average	USD$5.6853
200-day moving average	USD$6.4084
Wall St. target price	USD$13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.66

Buy Ardelyx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Ardelyx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ardelyx, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ardelyx price performance over time

Historical closes compared with the close of $5.83 from 2020-11-16

1 week (2020-11-23)	-1.69%
1 month (2020-10-30)	14.09%
3 months (2020-08-28)	3.55%
6 months (2020-05-29)	-20.46%

1 year (2019-11-29)	-21.53%
2 years (2018-11-30)	114.34%
3 years (2017-11-30)	-12.33%
5 years (2015-11-30)	-70.19%

Ardelyx financials

Revenue TTM	USD$8.3 million
Gross profit TTM	USD$4.7 million
Return on assets TTM	-30.58%
Return on equity TTM	-84.35%
Profit margin	0%
Book value	$1.642
Market capitalisation	USD$488.9 million

TTM: trailing 12 months

Shorting Ardelyx shares

There are currently 5.5 million Ardelyx shares held short by investors – that's known as Ardelyx's "short interest". This figure is 7.3% down from 5.9 million last month.

There are a few different ways that this level of interest in shorting Ardelyx shares can be evaluated.

Ardelyx's "short interest ratio" (SIR)

Ardelyx's "short interest ratio" (SIR) is the quantity of Ardelyx shares currently shorted divided by the average quantity of Ardelyx shares traded daily (recently around 687543.6795995). Ardelyx's SIR currently stands at 7.99. In other words for every 100,000 Ardelyx shares traded daily on the market, roughly 7990 shares are currently held short.

However Ardelyx's short interest can also be evaluated against the total number of Ardelyx shares, or, against the total number of tradable Ardelyx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ardelyx's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ardelyx shares in existence, roughly 60 shares are currently held short) or 0.0758% of the tradable shares (for every 100,000 tradable Ardelyx shares, roughly 76 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ardelyx.

Find out more about how you can short Ardelyx stock.

Ardelyx share dividends

We're not expecting Ardelyx to pay a dividend over the next 12 months.

Ardelyx share price volatility

Over the last 12 months, Ardelyx's shares have ranged in value from as little as $4.22 up to $8.815. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ardelyx's is 1.8627. This would suggest that Ardelyx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ardelyx overview

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Frequently asked questions

• What percentage of Ardelyx is owned by insiders or institutions?

  Currently 0.653% of Ardelyx shares are held by insiders and 85.955% by institutions.

• How many people work for Ardelyx?

  Latest data suggests 88 work at Ardelyx.

• When does the fiscal year end for Ardelyx?

  Ardelyx's fiscal year ends in December.

• Where is Ardelyx based?

  Ardelyx's address is: 34175 Ardenwood Boulevard, Fremont, CA, United States, 94555

• What is Ardelyx's ISIN number?

  Ardelyx's international securities identification number is: US0396971071

• What is Ardelyx's CUSIP number?

  Ardelyx's Committee on Uniform Securities Identification Procedures number is: 039697107